Cancer waiting times

62 days

All patients who have been referred by their GP or by a dentist on a suspected cancer pathway should receive their first definitive treatment within 62 days of referral receipt. We have achieved the 62-day target for the first quarter of 2018/19.

31 days 

All patients should have their first definitive treatment from deciding with their clinician on a treatment plan to actual commencement of treatment within 31 days.

We have achieved the overall 31-day target for June 2018.

31 day subsequent treatment for surgery, drugs and radiotherapy

All patients who are deemed clinically appropriate to treat by their clinician should receive any subsequent treatment within 31 days. This includes surgery, radiotherapy and any chemotherapy drugs.

We have achieved all of these 31-day targets for the month of June 2018. 

18 weeks

All patients who are referred for treatment should be treated within 18 weeks from receipt of referral. We have achieved all 18-week targets for the month of June 2018.

Last updated: July 2021

Christie stories during the COVID-19 pandemic

During the COVID-19 pandemic, we're doing all we can to make sure patients get the treatment, information and support they need. Read some stories from our patients and staff to find out what The Christie is doing at this difficult time.

View All
Corinne Faivre Finn
“We have seen a lot of our research staff return to the office. This has massively improved morale as it is a lot easier to connect with people.”
Corinne Faivre-Finn, Christie consultant
Read More
Read More
profile placeholder image
“The experience has allowed me to be able to hear what is not being said. The extraordinary strength and resilience of individuals as they greet you with a smile… when you are aware of the pain and anguish they will be going through.”
Digital services team, redeployed to telephone patients
Read More
Read More
“Of course, the COVID-19 virus has not gone away – we have to be cautious and we have to proceed in an appropriate way.”
Professor John Radford, director of research at The Christie
Read More
Read More